Soleno Therapeutics – Consensus Indicates Potential 344.6% Upside

Broker Ratings

Soleno Therapeutics found using ticker (SLNO) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 9 and 8 with the average target price sitting at 8.67. Given that the stocks previous close was at 1.95 this would imply there is a potential upside of 344.6%. The day 50 moving average is 1.94 and the 200 moving average now moves to 1.95. The company has a market capitalisation of $154m. You can visit the company’s website by visiting:

Soleno Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia and changed its name to Soleno Therapeutics in May 2017. Soleno Therapeutics was incorporated in 1999 and is headquartered in Redwood City, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index